[go: up one dir, main page]

WO2004067762A3 - Structure cristallisee hexamere a domaine nc1 de collagene de type iv - Google Patents

Structure cristallisee hexamere a domaine nc1 de collagene de type iv Download PDF

Info

Publication number
WO2004067762A3
WO2004067762A3 PCT/US2004/002187 US2004002187W WO2004067762A3 WO 2004067762 A3 WO2004067762 A3 WO 2004067762A3 US 2004002187 W US2004002187 W US 2004002187W WO 2004067762 A3 WO2004067762 A3 WO 2004067762A3
Authority
WO
WIPO (PCT)
Prior art keywords
hexamer
collagen
type
domain
crystallized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/002187
Other languages
English (en)
Other versions
WO2004067762A2 (fr
Inventor
Muirathinam Sundaramoorthy
Billy Hudson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas Medical Center
Original Assignee
University of Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas Medical Center filed Critical University of Kansas Medical Center
Publication of WO2004067762A2 publication Critical patent/WO2004067762A2/fr
Publication of WO2004067762A3 publication Critical patent/WO2004067762A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un hexamère à domaine NC1 cristallisé de collagène de type IV, ainsi que des procédés de fabrication de ce cristal. Selon l'invention, l'hexamère à domaine NC1 est cristallisé de manière que sa structure tridimensionnelle puisse être déterminée avec une résolution d'au moins 3 Å. L'invention concerne également un procédé d'élaboration de composés destinés à inhiber l'angiogenèse, la croissance tumorale, les métastases tumoraux, l'adhésion et/ou la prolifération de cellules endothéliales, et/ou des ensembles de lame ventrale. Ledit procédé consiste à analyser la structure tridimensionnelle d'un hexamère à domaine NC1 cristallisé de collagène de type IV obtenu au moyen du procédé selon l'invention, et à identifier et synthétiser des composés ciblant des régions du domaine NC1 dont l'importance pour l'ensemble hétérotrimère et hexamère de collagène de type IV a été identifiée par l'analyse. L'invention concerne par ailleurs des polypeptides élaborés au moyen des procédés selon l'invention d'élaboration rationnelle de substances thérapeutiques, sur la base de l'analyse de la structure hexamère à domaine NC1 de collagène de type IV.
PCT/US2004/002187 2003-01-27 2004-01-27 Structure cristallisee hexamere a domaine nc1 de collagene de type iv Ceased WO2004067762A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44313303P 2003-01-27 2003-01-27
US60/443,133 2003-01-27

Publications (2)

Publication Number Publication Date
WO2004067762A2 WO2004067762A2 (fr) 2004-08-12
WO2004067762A3 true WO2004067762A3 (fr) 2004-11-04

Family

ID=32825293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/002187 Ceased WO2004067762A2 (fr) 2003-01-27 2004-01-27 Structure cristallisee hexamere a domaine nc1 de collagene de type iv

Country Status (1)

Country Link
WO (1) WO2004067762A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1573025A4 (fr) 2001-07-27 2006-07-19 Univ Kansas Medical Center Structure cristallisee de l'hexamere du domaine nc1 du collagene de type iv
WO2012079088A2 (fr) * 2010-12-10 2012-06-14 The Johns Hopkins University Peptides mimétiques dérivés de collagène de type iv et leur utilisation pour traiter des maladies dépendantes de l'angiogenèse et de la lymphangiogenèse
KR102849034B1 (ko) * 2022-08-22 2025-08-26 주식회사 한국비엔씨 Pips 펩타이드를 포함하는 탈모 억제 또는 발모 촉진용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593900A (en) * 1989-07-07 1997-01-14 Tryggvason; Karl Immunological methods for the detection of the human type IV collagen α5 chain
US5856184A (en) * 1994-06-30 1999-01-05 Yale University Isolated domains of type IV collagen to modify cell and tissue interactions
WO2001051523A2 (fr) * 2000-01-07 2001-07-19 Beth Israel Deaconess Medical Center Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation
US6277558B1 (en) * 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
US6361994B1 (en) * 1995-06-30 2002-03-26 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α1 chain monomer of type IV collagen
WO2003012122A2 (fr) * 2001-07-27 2003-02-13 University Of Kansas Medical Center Structure cristallisee de l'hexamere du domaine nc1 du collagene de type iv

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593900A (en) * 1989-07-07 1997-01-14 Tryggvason; Karl Immunological methods for the detection of the human type IV collagen α5 chain
US6277558B1 (en) * 1990-11-30 2001-08-21 Kansas University Medical Center α-3 chain type IV collagen polynucleotides
US5856184A (en) * 1994-06-30 1999-01-05 Yale University Isolated domains of type IV collagen to modify cell and tissue interactions
US6361994B1 (en) * 1995-06-30 2002-03-26 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α1 chain monomer of type IV collagen
WO2001051523A2 (fr) * 2000-01-07 2001-07-19 Beth Israel Deaconess Medical Center Proteines et fragments de proteines anti-angiogeniques et leurs procede d'utilisation
WO2003012122A2 (fr) * 2001-07-27 2003-02-13 University Of Kansas Medical Center Structure cristallisee de l'hexamere du domaine nc1 du collagene de type iv

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
COLORADO P C ET AL: "ANTI-ANGIOGENIC CUES FROM VASCULAR BASEMENT MEMBRANE COLLAGEN", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 9, 1 May 2000 (2000-05-01), pages 2520 - 2526, XP001019102, ISSN: 0008-5472 *
MAESHIMA YOHEI ET AL: "Distinct antitumor properties of a type IV collagen domain derived from basement membrane", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 28, 14 July 2000 (2000-07-14), pages 21340 - 21348, XP002204077, ISSN: 0021-9258 *
MAESHIMA YOHEI ET AL: "Extracellular matrix-derived peptide binds to alphavbeta3 integrin and inhibits angiogenesis", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 34, 24 August 2001 (2001-08-24), pages 31959 - 31968, XP002296029, ISSN: 0021-9258 *
PETITCLERC E ET AL: "NEW FUNCTION FOR NON- COLLAGENOUS DOMAINS OF HUMAN COLLAGEN", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 11, 17 March 2000 (2000-03-17), pages 8051 - 8061, XP002144125, ISSN: 0021-9258 *
SUNDARAMOORTHY MUNIRATHINAM ET AL: "Crystal structure of NC1 domains. Structural basis for type IV collagen assembly in basement membranes", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 34, 23 August 2002 (2002-08-23), pages 31142 - 31153, XP002296030, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2004067762A2 (fr) 2004-08-12

Similar Documents

Publication Publication Date Title
Ahern et al. New discoveries and interpretations of hominid fossils and artifacts from Vindija Cave, Croatia
WO2003012122A3 (fr) Structure cristallisee de l'hexamere du domaine nc1 du collagene de type iv
ATE425277T1 (de) Verfahren zur herstellung eines sputtertargets und sputtertarget
Åhäll et al. Long-term convergence along SW Fennoscandia: 330 my of Proterozoic crustal growth
EP2502935A3 (fr) Anticorps améliorés dotés d'une fonction effectrice altérée et leurs procédés de fabrication
Jackson et al. Holocene loess deposition in Iceland: Evidence for millennial-scale atmosphere-ocean coupling in the North Atlantic
AU2002315157A1 (en) Methods of screening for ligands of target molecules
ATE412891T1 (de) Verbessertes toxizität-screening verfahren
WO2005000758A3 (fr) Substrat revetu d’une couche dielectrique et procede et installation pour sa fabrication
NZ595303A (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ATE541729T1 (de) Aus mindestens zwei benachbarten glaselementen bestehendes komplexes trennwandglas und verfahren zur herstellung des komplexen trennwandglases
WO2003004622A3 (fr) Proteines humaines secretees
ATE382053T1 (de) System zur antikörperexpression und- synthese
WO2005104259A3 (fr) Encapsulement d'un composant electronique organique, son procede de production et son utilisation
NO20060466L (no) Variable antibodies
Miracle et al. Last glacial climates,“Refugia”, and faunal change in Southeastern Europe: Mammalian assemblages from Veternica, Velika pećina, and Vindija Caves (Croatia)
WO2004067762A3 (fr) Structure cristallisee hexamere a domaine nc1 de collagene de type iv
AU2003244157A1 (en) Process for producing sustained-release composition
GB2393190A (en) Process for producing pulp
WO2009064006A1 (fr) PROCÉDÉ DE CRIBLAGE UTILISANT UN NOUVEAU SUBSTRAT EphA7 POUR LA γ-SECRÉTASE
Campisano et al. Tephrostratigraphy of the Hadar and Busidima Formations at Hadar, Afar Depression, Ethiopia
EP1801208A4 (fr) Anticorps anti-a33
WO2003067241A3 (fr) Capteur de gaz et son procede de production
DE502004010328D1 (de) Hydrogelhaltiges kompositmaterial, hergestellt durch elektrisch-ausgelöste präzipitation einer festphase
WO2004005920A3 (fr) Procede pour enrichir et pour depister des proteines prions pathologiques modifiees (prpsc)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase